Sign in

You're signed outSign in or to get full access.

Joanne Winch

Managing Director at Citibank, N.A.

Joanne Wuensch is a Managing Director at Citi Research, focusing on Medical Technology and Hospital Supplies. She has previously covered sectors such as cardiology, diabetes, orthopedic, ophthalmology, and respiratory at other firms like BMO Capital Markets. Wuensch joined Citi in January 2020 after spending 18 years at BMO Capital Markets. She holds a Master's in Public Affairs from New York University and a Bachelor's in Psychology from the University of Delaware. Wuensch's career spans multiple roles at firms including ABN Amro, ING Barings, UBS Securities, and JP Morgan. However, specific performance metrics or company coverage details were not found for Joanne Winch.

Joanne Winch's questions to BAXTER INTERNATIONAL (BAX) leadership

Question · Q4 2025

Joanne Winch inquired about the philosophy behind constructing the 2026 guidance, specifically how Baxter aimed to ensure deliverability and consistency with its 'Say-Do Ratio.'

Answer

EVP and CFO Joel Grade stated that the guidance is prudent, reflective of current information, and transparent about challenges and actions, incorporating key assumptions like the Novum situation, IV solutions rebasing, pharma challenges, product mix impacts, reduced pricing contribution, and EPS impacts. President and CEO Andrew Hider echoed this, adding that Baxter GPS will be foundational to driving accountability and continuous improvement, aiming to enhance the 'Say-Do Ratio' throughout the year.

Ask follow-up questions

Fintool

Fintool can predict BAXTER INTERNATIONAL logo BAX's earnings beat/miss a week before the call

Joanne Winch's questions to BOSTON SCIENTIFIC (BSX) leadership

Question · Q3 2025

Joanne Winch inquired about two broader medtech impacts: the performance of Boston Scientific's China business amidst VBP pressures and any observed procedure pull-forward due to anticipated Affordable Care Act or Medicare cuts.

Answer

Chairman and CEO Mike Mahoney stated that Boston Scientific has not observed any signals indicating procedural pull-forward. Regarding China, he emphasized the team's strong performance, achieving mid-teens growth in the quarter and maintaining confidence in double-digit growth over the long-range plan. This growth is attributed to offsetting VBP price pressures with new innovation and launches in ICTX, EP, and Watchman Flex Pro, alongside expanding customer coverage.

Ask follow-up questions

Fintool

Fintool can predict BOSTON SCIENTIFIC logo BSX's earnings beat/miss a week before the call

News for Covered Companies

Boston Scientific Crashes 16% in Worst Day Since 1998 as EP Growth Fears Spook Investors

Boston Scientific Crashes 16% in Worst Day Since 1998 as EP Growth Fears Spook Investors

BSXFeb 4
Boston Scientific Pays $14.5 Billion for Penumbra, Betting Big on Thrombectomy

Boston Scientific Pays $14.5 Billion for Penumbra, Betting Big on Thrombectomy

BSXJan 15